Literature DB >> 25674294

Immunohistochemical expression of matrix metalloproteinase-9 and inhibitor of matrix metalloproteinase-1 in prostate adenocarcinoma.

Igor I Babichenko1, Mikhail I Andriukhin2, Sergey Pulbere2, Artem Loktev2.   

Abstract

An immunohistochemical study on the cells proliferative activity by Ki-67 protein and localization of the matrix metalloproteinase-9 and the inhibitor of matrix metalloproteinase-1 was carried out at the benign prostatic hyperplasia (BPH) and the adenocarcinoma (AC) of different Gleason's grades. A significant decrease of the MMP-9 and TIMP-1 level in the AC of different gradations was observed. A moderate positive correlation between the Gleason score and cell proliferation Ki-67 index (rs = 0.674) and a moderate negative correlation with the level of such a score and expression of MMP-9 (rs = -0.660) was detected. A weak negative correlation exists also between the level of proliferative activity of secretory cells and the expression of MMP-9 by tumor cells (rs = -0.369). The invasive properties of AC cells that promote a degradation of the basal membrane and connective tissue in prostate may be explained by the imbalance between the MMP-9 and TIMP-1, which expression is significantly reduced in AC, in comparison with BPH.

Entities:  

Keywords:  Adenocarcinoma of the prostate; Ki-67; MMP-9; TIMP-1; collagen IV

Mesh:

Substances:

Year:  2014        PMID: 25674294      PMCID: PMC4313967     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  27 in total

Review 1.  Structural basis of matrix metalloproteinase function.

Authors:  Wolfram Bode
Journal:  Biochem Soc Symp       Date:  2003

Review 2.  Tissue inhibitors of metalloproteinases: evolution, structure and function.

Authors:  K Brew; D Dinakarpandian; H Nagase
Journal:  Biochim Biophys Acta       Date:  2000-03-07

3.  Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues.

Authors:  B L Lokeshwar; M G Selzer; N L Block; Z Gunja-Smith
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

4.  Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients.

Authors:  William K Oh; Roberto Vargas; Susanna Jacobus; Kim Leitzel; Meredith M Regan; Peter Hamer; Karen Pierce; Sheryl Brown-Shimer; Walter Carney; Suhail M Ali; Philip W Kantoff; Allan Lipton
Journal:  Cancer       Date:  2010-09-22       Impact factor: 6.860

5.  Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer?

Authors:  Silvan Boxler; Valentin Djonov; Thomas M Kessler; Ruslan Hlushchuk; Lucas M Bachmann; Ulrike Held; Regula Markwalder; George N Thalmann
Journal:  Am J Pathol       Date:  2010-10-01       Impact factor: 4.307

6.  Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.

Authors:  B Brehmer; S Biesterfeld; G Jakse
Journal:  Prostate Cancer Prostatic Dis       Date:  2003       Impact factor: 5.554

7.  Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.

Authors:  Anne-Sofie Schrohl; Mads N Holten-Andersen; Harry A Peters; Maxine P Look; Marion E Meijer-van Gelder; Jan G M Klijn; Nils Brünner; John A Foekens
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

8.  Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.

Authors:  Hideaki Miyake; Mototsugu Muramaki; Toshifumi Kurahashi; Atsushi Takenaka; Masato Fujisawa
Journal:  Urol Oncol       Date:  2008-10-10       Impact factor: 3.498

9.  Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression.

Authors:  Giancarlo Castellano; Grazia Malaponte; Maria C Mazzarino; Mariangela Figini; Francesco Marchese; Pietro Gangemi; Salvatore Travali; Franca Stivala; Silvana Canevari; Massimo Libra
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

10.  In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases.

Authors:  P Mignatti; R Tsuboi; E Robbins; D B Rifkin
Journal:  J Cell Biol       Date:  1989-02       Impact factor: 10.539

View more
  4 in total

1.  Influence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated Proteins.

Authors:  Rasheena Edmondson; Audrey F Adcock; Liju Yang
Journal:  PLoS One       Date:  2016-06-28       Impact factor: 3.240

Review 2.  The Role of the Metzincin Superfamily in Prostate Cancer Progression: A Systematic-Like Review.

Authors:  Marley J Binder; Alister C Ward
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923

3.  Tissue expression of MMP-9, TIMP-1, RECK, and miR338-3p in prostate gland: can it predict cancer?

Authors:  Rodolfo Pacheco de Moraes; Ruan Pimenta; Fernando Noboru Cabral Mori; Gabriel Arantes Dos Santos; Nayara Izabel Viana; Vanessa Ribeiro Guimarães; Juliana Alves de Camargo; Katia Ramos Moreira Leite; Miguel Srougi; William Carlos Nahas; Sabrina T Reis
Journal:  Mol Biol Res Commun       Date:  2021-12

4.  Effect of Hypoxia on DDR1 Expression in Pituitary Adenomas.

Authors:  Shouchun Li; Zhiwen Zhang; Jinghui Xue; Xiaoming Guo; Shuli Liang; Aijun Liu
Journal:  Med Sci Monit       Date:  2015-08-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.